Saturday 17 October 2026
Export LNAI’s income statement to Excel — free account
Lunai Bioworks Inc.
LNAI Healthcare Biotechnology
Lunai Bioworks Inc.’s revenue for fiscal 2026 (year ended June 2026) was $52,000.00. In the quarter to June 2026, EPS grew 99.0% and free cash flow fell 1.65%, each against the same quarter a year earlier. Revenue growth for ten consecutive years, operating cash flow growth for five.
0.68
0.15
−18.07%
Follow LNAI
Lunai Bioworks Inc. (LNAI) P/E ratio
Lunai Bioworks Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 185× (June 2020) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Jun 2016 | 0.0× | — |
| Dec 2015 | 0.0× | — |
Against its own ten years
Low 0.0×
High 185×
Ten-year median
0.0×
Current reading's percentile
98
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| OSRH OSR Health, Inc. compare | n/m |
| LIMN Liminatus Pharma Inc. compare | n/m |
| NCNA NuCana PLC Sponsored ADR compare | n/m |
| ADTX Aditxt, Inc. compare | n/m |
| PMCB Nuvilex Inc. compare | n/m |
| LNAI Lunai Bioworks Inc. | n/m |
| JUNS Jupiter Neurosciences, Inc. compare | n/m |
| ENLV Enlivex Ltd. compare | 0.0× |
| AZTR Azitra, Inc. compare | 1.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)